David Stack Appointed to Amarin Board of Directors
BEDMINSTER, N.J., and DUBLIN, Ireland, Dec. 12, 2012 (GLOBE NEWSWIRE) --
Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on
the commercialization and development of therapeutics to improve
cardiovascular health, today announced that David Stack, President and Chief
Executive Officer of Pacira Pharmaceuticals, has joined Amarin's Board of
Directors as an independent director effective December 10, 2012.
Mr. Stack has more than 25 years of successful pharmaceutical industry
experience. Beyond his current role as President, Chief Executive Officer and
Director of Pacira Pharmaceuticals, Mr. Stack is also a Managing Director at
MPM Capital, and Founding Partner of Stack Pharmaceuticals, Inc. Mr. Stack's
extensive experience includes, from 2001 to 2004, President, CEO and a
Director of The Medicines Company where he was recognized as the Ernst and
Young Entrepreneur of the Year in 2003. Prior to The Medicines Company, Mr.
Stack was the President and General Manager of Innovex Inc., Vice President of
Business Development and Marketing for Immunomedics, Inc., and Director of
Business Development and Planning for Infectious Disease, Oncology and
Virology of Roche Laboratories. Mr. Stack holds a degree in pharmacy from
Albany College and a BS in biology from Siena College where he is currently a
Trustee. Mr. Stack is a Director of Medivo, Inc. and PepTx, Inc.
"The addition of Dave Stack further expands on the operational experience of
the Amarin Board of Directors and enhances the Board's outstanding talent and
pharmaceutical industry expertise," said Joseph Zakrzewski, Amarin's Chairman
and Chief Executive Officer. "Dave's insights will be valuable as we continue
toward the Vascepa commercial launch early in the first quarter of 2013."
"Amarin has a unique asset in Vascepa, a great management team and strong
momentum as it seeks to lead the next generation of lipid management," stated
Mr. Stack. "I look forward to working with Amarin's Board and management team
as the company capitalizes on such a significant market opportunity."
Amarin Corporation plc is a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health. Amarin's product development program leverages its extensive
experience in lipid science and the potential therapeutic benefits of
polyunsaturated fatty acids. Vascepa^® (icosapent ethyl), Amarin's first FDA
approved product, is a patented, ultra pure omega-3 fatty acid product
comprising not less than 96% EPA. For more information about Vascepa visit
www.vascepa.com. For more information about Amarin visit www.amarincorp.com.
The Amarin Corporation plc logo is available at
This press release contains forward-looking statements, including statements
about the timing of a commercial launch of Vascepa and preparations for
commercial launch. These forward-looking statements are not promises or
guarantees and involve substantial risks and uncertainties. Among the factors
that could cause actual results to differ materially from those described or
projected herein include risks associated with the launch of a new
pharmaceutical product, such as adequacy of supply and compliance with
regulatory requirements. A further list and description of these risks,
uncertainties and other risks associated with an investment in Amarin can be
found in Amarin's filings with the U.S. Securities and Exchange Commission,
including its most recent Quarterly Report on Form 10-Q. Existing and
prospective investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. Amarin
undertakes no obligation to update or revise the information contained in this
press release, whether as a result of new information, future events or
circumstances or otherwise.
CONTACT: Amarin contact information:
Stephen D. Schultz
Investor Relations and Corporate Communications
In U.S.: +1 (908) 719-1315
Press spacebar to pause and continue. Press esc to stop.